Clinical Trials Logo
  1. Home
  2. Other
  3. NCT06125080

The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ：Single-arm, Prospective, Open Clinical Study — UTILIZABLE  

TNBC - Triple-Negative Breast Cancer Clinical Trial

Official title:
The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ：Single-arm, Prospective, Open Clinical Study

Clinical Trial Summary

This is a multicenter, open-label, single-arm clinical study designed to evaluate the safety and efficacy of Utidelone plus Tirelizumab and Bevacizumab for advanced or metastatic triple-negative breast cancer (TNBC).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06125080
Study type Interventional
Source Tongji Hospital
Contact Huihua Xiong, PI
Phone 027-83663405
Email xionghuihua@hotmail.com
Status Recruiting
Phase Phase 2
Start date October 30, 2023
Completion date October 30, 2026
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05491694 - To Evaluate the Efficacy of Toripalimab Combined With Chemotherapy After HIFU Induction in the Treatment of Early Triple-negative Breast Cancer Phase 2
Recruiting NCT05396612 - Role of the Immune Environment in Response to Therapy in Breast Cancer
Completed NCT03719326 - A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies Phase 1
Recruiting NCT04674306 - Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer Early Phase 1
Recruiting NCT06230185 - ctDNA Based MRD Testing for NAC Monitoring in TNBC
Recruiting NCT05491226 - Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation Phase 2
Withdrawn NCT05062174 - Breast Cancer BRCA1 Carriers: a Pilot Study
Recruiting NCT06059469 - PSMA-PET/CT to Assess the Expression of Specific Membrane Antigen (PSMA) in Patients With Progressive Triple-negative Breast Cancer. Phase 2
Terminated NCT03875313 - Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors Phase 1/Phase 2
Completed NCT03057600 - Study of CB-839 in Combination w/ Paclitaxel in Participants of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC) Phase 2
Recruiting NCT04706962 - TH1902 in Patients With Advanced Solid Tumors Phase 1
Recruiting NCT05274451 - A Study to Investigate LYL797 in Adults With Solid Tumors Phase 1
Not yet recruiting NCT04755868 - Talazoparib Maintenance Therapy in Triple-negative Breast Cancer Phase 2
Recruiting NCT01042379 - I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer Phase 2
Recruiting NCT05848739 - A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors Phase 1
Not yet recruiting NCT06358573 - Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK Phase 2
Active, not recruiting NCT05451849 - A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer Phase 1/Phase 2
Recruiting NCT05914961 - Immunotherapy-related CRP Kinetics in Early and Metastatic Triple-negative Breast Cancer
Completed NCT05390710 - PhI to Solid Tumors and PhII to Locally Advanced or mTNBC Phase 1
Recruiting NCT05862064 - PD-1 Combined With Adjuvant Chemotherapy and Antivascular Therapy Versus Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer Phase 3